Tiger Aesthetics Splits Sales Force Into BioBody and BioDerma Units

Tiger Aesthetics is restructuring its commercial operations into two specialized divisions, BioBody and BioDerma, to capture a broader share of the medical aesthetics market. This move aligns with a major hiring push intended to more than double the company's sales force by the end of 2026 to support its expanding adipose tissue portfolio.

The company, based in Conshohocken, Pennsylvania, is partitioning its sales teams to better serve distinct clinical audiences. BioBody will focus exclusively on board-certified plastic and cosmetic surgeons, while BioDerma will target dermatologists and medical spa providers. Both divisions are designed to streamline the commercial rollout of the company's structural adipose tissue products, including the existing alloClae treatment for body contouring and the upcoming dermaClae line for facial rejuvenation, slated for launch in early 2027.

Stephen Stafford has been appointed to lead the BioDerma division, tasked with building out a dedicated sales organization for the dermatology segment. According to Caro Van Hove, President of Tiger Aesthetics, this specialization allows the company to provide more focused resources to providers while scaling infrastructure. The firm plans to reach a total of 100 sales representatives by the end of 2026, with an objective to double the size of its commercial footprint annually thereafter. This strategy follows the company’s broader integration of medical devices, such as the Avéli cellulite reduction system and Sientra implants, into its regenerative medicine platform.